Cutler Group LP Ocugen, Inc. Call Options Transaction History

Cutler Group LP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 07, 2023	SELL	$1.11 - $1.87 $111 - $187	-100 Reduced 0.18%	56,900 $0
Q3 2022 Oct 25, 2022	SELL	$1.75 - $3.1 $11,200 - $19,840	-6,400 Reduced 10.09%	57,000 $3,000
Q2 2022 Aug 04, 2022	SELL	$1.83 - $3.45 $141,642 - $267,030	-77,400 Reduced 54.97%	63,400 $8,000
Q1 2022 Apr 14, 2022	BUY	$2.34 - $4.72 $163,566 - $329,928	69,900 Added 98.59%	140,800 $40,000
Q4 2021 Jan 18, 2022	BUY	$4.38 - $15.67 $13,140 - $47,010	3,000 Added 4.42%	70,900 $16,000
Q3 2021 Oct 26, 2021	SELL	$6.36 - $8.51 $414,036 - $554,001	-65,100 Reduced 48.95%	67,900 $61,000
Q2 2021 Jul 19, 2021	BUY	$5.52 - $15.68 $619,896 - $1.76 Million	112,300 Added 542.51%	133,000 $126,000
Q1 2021 Apr 26, 2021	BUY	$1.66 - $15.81 $34,362 - $327,267	20,700 New	20,700 $10,000

124

78.3M

535K

523K

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $191M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.